PT Central Proteina Prima Tbk
PT Central Proteina Prima Tbk, together with its subsidiaries, operates as an integrated aquaculture shrimp and foods producer company in Indonesia and internationally. It operates through Feeds business, Food business, and Others segments. The company engages in industry, livestock and agriculture, trading, farming, hatchery, and trading and services. It offers shrimp feed, fish feed, cat food, … Read more
PT Central Proteina Prima Tbk (4PT) - Net Assets
Latest net assets as of June 2025: €3.86 Trillion EUR
Based on the latest financial reports, PT Central Proteina Prima Tbk (4PT) has net assets worth €3.86 Trillion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.84 Trillion) and total liabilities (€2.98 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.86 Trillion |
| % of Total Assets | 56.43% |
| Annual Growth Rate | 9.56% |
| 5-Year Change | 404.34% |
| 10-Year Change | 80.02% |
| Growth Volatility | 354.82 |
PT Central Proteina Prima Tbk - Net Assets Trend (2013–2024)
This chart illustrates how PT Central Proteina Prima Tbk's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PT Central Proteina Prima Tbk (2013–2024)
The table below shows the annual net assets of PT Central Proteina Prima Tbk from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.57 Trillion | +4.36% |
| 2023-12-31 | €3.42 Trillion | +7.48% |
| 2022-12-31 | €3.18 Trillion | +11.21% |
| 2021-12-31 | €2.86 Trillion | +304.36% |
| 2020-12-31 | €707.58 Billion | +114.75% |
| 2019-12-31 | €329.49 Billion | -51.14% |
| 2018-12-31 | €674.34 Billion | +137.87% |
| 2017-12-31 | €-1.78 Trillion | -1084.30% |
| 2016-12-31 | €180.88 Billion | -90.88% |
| 2015-12-31 | €1.98 Trillion | +118.16% |
| 2014-12-31 | €908.66 Billion | -30.51% |
| 2013-12-31 | €1.31 Trillion | -- |
Equity Component Analysis
This analysis shows how different components contribute to PT Central Proteina Prima Tbk's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 110208000000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €6.57 Trillion | 184.15% |
| Total Equity | €3.57 Trillion | 100.00% |
PT Central Proteina Prima Tbk Competitors by Market Cap
The table below lists competitors of PT Central Proteina Prima Tbk ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tsky Co.,Ltd
TWO:6784
|
$6.90 Million |
|
IFS Capital (Thailand) Public Company Limited
BK:IFS
|
$6.91 Million |
|
Tontek Design Technology Ltd
TWO:5487
|
$6.91 Million |
|
Artius II Acquisition Inc. Rights
NASDAQ:AACBR
|
$6.91 Million |
|
Huddlestock Fintech As
OL:HUDL
|
$6.90 Million |
|
FACT II Acquisition Corp. Warrant
NASDAQ:FACTW
|
$6.90 Million |
|
Study King Co., Ltd.
TWO:6780
|
$6.90 Million |
|
Ekadharma International Tbk
JK:EKAD
|
$6.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PT Central Proteina Prima Tbk's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,416,679,000,000 to 3,566,057,000,000, a change of 149,378,000,000 (4.4%).
- Net income of 319,976,000,000 contributed positively to equity growth.
- Dividend payments of 600,000,000 reduced retained earnings.
- Other factors decreased equity by 169,998,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €319.98 Billion | +8.97% |
| Dividends Paid | €600.00 Million | -0.02% |
| Other Changes | €-170.00 Billion | -4.77% |
| Total Change | €- | 4.37% |
Book Value vs Market Value Analysis
This analysis compares PT Central Proteina Prima Tbk's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €-43.85 | €0.00 | x |
| 2018-12-31 | €11.29 | €0.00 | x |
| 2019-12-31 | €5.50 | €0.00 | x |
| 2020-12-31 | €11.84 | €0.00 | x |
| 2021-12-31 | €47.99 | €0.00 | x |
| 2022-12-31 | €53.37 | €0.00 | x |
| 2023-12-31 | €57.35 | €0.00 | x |
| 2024-12-31 | €59.86 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PT Central Proteina Prima Tbk utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.97%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.45%
- • Asset Turnover: 1.38x
- • Equity Multiplier: 1.88x
- Recent ROE (8.97%) is above the historical average (-64.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 92.29% | 15.63% | 1.07x | 5.52x | €1.07 Trillion |
| 2014 | -43.15% | -4.12% | 1.33x | 7.86x | €-479.44 Billion |
| 2015 | -60.74% | -13.37% | 0.99x | 4.60x | €-1.40 Trillion |
| 2016 | -1081.58% | -23.12% | 1.17x | 39.84x | €-2.01 Trillion |
| 2017 | 0.00% | -40.09% | 0.94x | 0.00x | €-2.46 Trillion |
| 2018 | 256.09% | 23.31% | 1.12x | 9.77x | €1.66 Trillion |
| 2019 | -106.59% | -4.86% | 1.20x | 18.32x | €-381.82 Billion |
| 2020 | 54.02% | 5.03% | 1.20x | 8.97x | €310.39 Billion |
| 2021 | 77.37% | 27.55% | 1.25x | 2.26x | €1.93 Trillion |
| 2022 | 11.75% | 4.53% | 1.21x | 2.15x | €55.76 Billion |
| 2023 | 11.75% | 4.45% | 1.32x | 2.01x | €59.80 Billion |
| 2024 | 8.97% | 3.45% | 1.38x | 1.88x | €-36.63 Billion |
Industry Comparison
This section compares PT Central Proteina Prima Tbk's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PT Central Proteina Prima Tbk (4PT) | €3.86 Trillion | 92.29% | 0.77x | $6.90 Million |
| Hanna Capital Corp (04U1) | $-79.29K | 0.00% | 0.00x | $116.52K |
| WESTMINSTER RES (08W) | $4.66 Million | -31.33% | 0.12x | $5.16 Million |
| Axonics Inc (0I3) | $570.14 Million | -10.47% | 0.16x | $3.29 Billion |
| Global Bioenergies SA (1DK) | $14.81 Million | -86.04% | 0.89x | $369.68K |
| GIEAG Immobilien AG (2GI) | $41.80 Million | 40.21% | 8.93x | $15.57K |
| 2invest AG (2INV) | $82.61 Million | -2.29% | 0.06x | $13.67 Million |
| DGH Deutsche Grundwert Holding AG (5TR) | $0.00 | 0.00% | 0.00x | $18.45K |
| SOFTCHOICE CORP. (90Q) | $58.23 Million | -19.76% | 10.01x | $470.36 Million |
| ALBA SE (ABA) | $142.95 Million | 5.25% | 0.45x | $5.10 Million |